Monday, August 28, 2023
Specialised Therapeutics has recently announced a collaboration with Treeway to bring a new therapy TW001 to Australia and New Zealand for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the most common form of Motor Neurone Disease (MND).
Under the terms of agreement, Specialised Therapeutics takes charge of various aspects such as marketing, regulatory processes, and distribution of TW001 for ALS/MND in Australia and New Zealand.
TW001, the innovative therapy, is an oral formulation of edaravone. Its mechanism of action involves reducing the oxidative damage that contributes to the death of neurons in ALS. Currently, TW001 is undergoing evaluation in a crucial phase III clinical trial called ADORE, being conducted at nearly 40 global sites.
Amyotrophic Lateral Sclerosis (ALS) is a prevalent motor neuron disease marked by the progressive degeneration of motor neurons in the spinal cord and brain. This degeneration leads to gradual paralysis, often resulting in death within 2 to 5 years after diagnosis.
ALS is relatively rare disease affecting individuals aged between 40 to 70, with slightly more cases occurring in men than in women. While 10-15 percent of cases have a genetic or familial link, the remaining 85-90 percent are classified as sporadic cases, where the exact cause is not yet known.
